Anti-LDHA

Evaluated by Western Blotting in HepG2 cell lysate.

Western Blotting Analysis: 0.2 µg/mL of this antibody detected LDHA in 10 µg of HepG2 cell lysate.

Anti-LDHA, Cat. No. ABN896, is a highly specific rabbit polyclonal antibody, that targets L-lactate dehydrogenase A chain and has been tested in Immunocytochemistry, Immunohistochemistry (Paraffin), and Western Blotting.

Immunocytochemistry Analysis: A 1:500 dilution from a representative lot detected LDHA in HUVECs and HeLa cells.

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected LDHA in rat testis, human prostate cancer and kidney tissue sections.

Research Category
Neuroscience

This rabbit polyclonal targeted epitope region is present in human LDHA spliced isoforms 1, 3, and 4, but absent from isoforms 2 and 5, reported by UniProt (P00338).

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

L-lactate dehydrogenase A chain (EC 1.1.1.27; UniProt P00338; also known as Cell proliferation-inducing gene 19 protein, LDH muscle subunit, LDH-A, LDH-M, Renal carcinoma antigen NY-REN-59) is encoded by the LDHA (also known as GSD11, PIG19) gene (Gene ID 3939) in human. Originally described by Otto Warburg and now commonly known as the Warburg effect refers to the phenomenon that many tumor cells use aerobic glycolysis instead of mitochondrial respiration for energy production to support cell growth and proliferation. Enzymes involved in the complex network of metabolic pathways are therefore being studied as potential targets for cancer treatment. Lactate dehydrogenase (LDH) is a tetrameric enzyme composed of two different subunits, LDHA and LDHB, which can assemble into five different combinations (LDH1 is comprised of four LDHB subunits; LDH2 contains three LDHB and one LDHA subunit; LDH3 contains two LDHB and two LDHA subunits; LDH4 contains one LDHB and three LDHA subunits; LDH5 contains four LDHA subunits). LDHB is ubiquitously expressed and the predominant isoform in heart muscle, while LDHA is the predominant isoform in skeletal muscle and other highly glycolytic tissues. LDH catalyzes the reversible conversion of pyruvate into lactate. An upregulation of LDH therefore reduces the oxygen dependency and ensures an efficient anaerobic/glycolytic metabolism in tumor cells. Upregulated LDHA has been observed in hepatocellular carcinoma, breast, pancreatic, and prostate cancers. Inhibition of LDHA reduced cell malignant transformation and tumor formation. Serum LDHB level is also reported to elevate in lung cancer patients and progressively increase with the clinical stage of non-small cell lung cancer (NSCLC).

~37 kDa observed. 36.56/39.71/30.07 kDa (human isoform 1/3/4) and 36.32 kDa (rat) calculated (Met1 removed). Uncharacterized band(s) may appear in some lysates.

KLH-conjugated linear peptide corresponding to a C-terminal region sequence of human LDHA.

Concentration: Please refer to lot specific datasheet.

Replaces: ABN311

Affinity purified.

Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Stable for 1 year at 2-8°C from date of receipt.